HCV Policy & Advocacy
Obamacare Deadline Coming Up, Guide Offers Covered California Advice for HIV, HCV, PrEP
- Details
- Category: HIV Policy & Advocacy
- Published on Thursday, 11 December 2014 00:00
- Written by HIVandHepatitis.com
December 15 is the deadline to enroll in Affordable Care Act (ACA or "Obamacare") health plans for insurance coverage starting on January 1, 2015. Finding the right plan can be tricky for people with HIV or hepatitis C, and for those who want coverage for Truvada for pre-exposure prophylaxis (PrEP), but there are resources to help.
Gilead Announces Generic Licensing Agreements for Hepatitis C Drug Sofosbuvir
- Details
- Category: HCV Treatment
- Published on Tuesday, 16 September 2014 00:00
- Written by Gilead Sciences
Gilead Sciences announced this week that it has granted a license to 7 generic drug companies in India to produce cheaper versions of its groundbreaking hepatitis C polymerase inhibitor sofosbuvir (Sovaldi) and its forthcoming sofosbuvir/ledipasvir coformulation for use in more than 90 developing countries.
EASL 2014: Idenix Hepatitis C Drugs Look Promising in Early Studies
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 06 May 2014 00:00
- Written by HIVandHepatitis.com
Idenix Pharmaceuticals' hepatitis C virus NS5A inhibitor samatasvir (formerly IDX179) plus Janssen's HCV protease inhibitor simeprevir (Olysio) and ribavirin produced early sustained virological response rates of about 80% in a small study presented at the 49th EASL International Liver Congress last month in London. Another study showed that the company's HCV polymerase inhibitor candidate IDX21437 looks good in preclinical studies and is a potential once-daily partner for samatasvir in interferon-free regimens.
Community Leaders, HIV Doctors Oppose Hepatitis C Treatment Barriers
- Details
- Category: HCV Policy & Advocacy
- Published on Friday, 12 September 2014 00:00
- Written by HIVandHepatitis.com
A coalition of hepatitis C advocacy organizations and medical providers has issued an open letter to the Secretary of Health and Human Services calling for an end to restrictions on access to hepatitis C treatment by private insurers and public payers seeking to avoid the cost of newly approved direct-acting antivirals. HIV medical providers also called for reducing barriers to treatment, including restrictions on which medical specialists may treat people with hepatitis C.
EASL 2014: European Liver Specialists Recommend Use of Newest Hepatitis C Drugs
- Details
- Category: HCV Treatment Guidelines
- Published on Saturday, 12 April 2014 00:00
- Written by Keith Alcorn
The European Association for the Study of the Liver (EASL) has issued new guidelines for the treatment of hepatitis C, which recommend that wherever possible, patients should be treated with the newest direct-acting antivirals. The guidelines also recommend physicians should "mix and match" antivirals from different companies to get the most potent regimens.
More Articles...
- EASL 2014: WHO Recommends Global Use of Newest Hepatitis C Drugs, Urges Price Reductions
- U.S. Government Releases Updated Viral Hepatitis Action Plan
- Doctors & Advocates Demand Better Health Coverage for HIV & Hepatitis
- IAS 2013: Experts Discuss Role of Drug Policy in HIV, Hepatitis, and TB Epidemics
Web Design and Development by